WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

2024.01.18
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy.
New Data on KRAS G12C Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer

New Data on KRAS G12C Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer

2023.10.13
The 2023 annual meeting of the American Association for Cancer Research (AACR) was held in Orlando, USA, from April 14th to 19th, 2023. Various important basic and clinical research results were presented at the conference, including the latest results of a Phase I study of IBI351 monotherapy in patients with advanced solid tumors from China. According to the latest data from this Phase I dose-escalation study (NCT05005234), the Phase II recommended dose of IBI351 monotherapy for advanced KRAS G12C mutated non-small cell lung cancer (NSCLC) patients shows good safety and promising efficacy.
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

2023.10.12
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy. [1,2]